Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Fig. 1

a–e Tumor uptake (%IA/g) of 111In-DOTATATE as function of time and injected mass of peptide (0.03–3 nmol, n = 4/cohort). The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g). f Predicted absorbed tumor dose of 213Bi-DOTATATE based on 111In-DOTATATE tumor biodistribution results. The injected mass of peptide expressed on x-axis and the estimated mean radiation absorbed dose (Gy) per injected MBq 213Bi-DOTATATE on the y-axis

Back to article page